Patent Case Watch

Patent opinions from the Eastern District of Texas and the U.S. Court of Appeals for the Federal Circuit

Fed. Cir.

UCB, Inc. v. Watson Laboratories Inc., No. 18-1397 (Fed. Cir. June 24, 2019)

Affirmed
Infringement Invalidity (§ 102/§ 103) Doctrine of Equivalents
Court
U.S. Court of Appeals for the Federal Circuit
Case No.
No. 18-1397
Also Docketed
No. 18-1453 (consolidated; same document)
Decided
June 24, 2019
Judge
Chen, J.
Document
Precedential Opinion
Length
34 pages

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

This appeal concerns UCB, Inc., UCB Manufacturing Ireland Limited, UCB Pharma GmbH, and LTS Lohman Therapie-Systeme AG (UCB)’s U.S. Patent Nos. 6,884,4341 and 8,232,414.2 The ’434 patent claims a transdermal ther- apeutic system comprising rotigotine, a drug used for the treatment of Parkinson’s disease. The ’414 patent claims a polymorph of rotigotine. The United States District Court for the District of Del aware found that Watson Laborato- ries Inc. and Actavis Laboratories UT, Inc.

Download Opinion (PDF)

Source: govinfo.gov USCOURTS collection · retrieved July 23, 2026 · Report an error